Not applicableStudy completedNCT07086196
What this trial is testing
Real-World Outcomes of Ribociclib in First-Line Treatment for Metastatic HR+/HER2- Breast Cancer
Who this might be right for
Metastatic HR+/HER2- Breast Cancer
Novartis Pharmaceuticals 350